📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-22 11:49
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Infinium Pharmachem Assigned [ICRA]BBB (Stable) Rating for ₹52.20 Cr Credit Facilities
Infinium Pharmachem Limited has received a new credit rating from ICRA Limited of [ICRA]BBB (Stable) across ₹52.20 crore of bank credit facilities. The rated facilities include ₹45.25 crore in fund-based cash credit limits, ₹6.84 crore in term loans, and ₹0.11 crore in unallocated limits. The total rated bank limits represent approximately 15% of the company's TTM revenue of ₹346 crore and 45% of its net worth of ₹116 crore. The facilities are distributed across ICICI Bank and State Bank of India.
Confidence: HIGH
What changedICRA assigned a new credit rating of [ICRA]BBB with a Stable outlook for bank facilities totalling ₹52.20 crore.
Why it mattersEstablishes formal credit assessment by a recognized rating agency, reflecting adequate credit quality and moderate safety regarding timely servicing of financial obligations.
Total rated bank facilities: Rs. 52.20 croreFund-based cash credit: Rs. 45.25 croreFund-based term loan: Rs. 6.84 croreRated facilities vs TTM revenue: ~15.1%Rated facilities vs Net worth: ~45.0%
📅 Short termNeutral operational impact; validates the company's current banking lines and creditworthiness with key lenders (SBI, ICICI).
📈 Long termSupports institutional borrowing access at competitive interest rates as the company scales API manufacturing operations.
⚠ Risk flags
- Subject to annual surveillance and covenant adherence on bank facilities
Key Highlights
ICRA assigned [ICRA]BBB (Stable) rating to total credit facilities of ₹52.20 crore
Cash credit limits rated at ₹45.25 crore (₹19.00 crore with ICICI Bank and ₹26.25 crore with State Bank of India)
Term loan facilities rated at ₹6.84 crore (₹3.72 crore with ICICI Bank and ₹3.12 crore with State Bank of India)
Total rated limits equal ~45% of net worth (₹116 crore) and ~15% of TTM revenue (₹346 crore)
👀 What to Watch
Track future borrowing costs and working capital utilization in upcoming quarterly results, as the stable investment-grade rating establishes a baseline for institutional debt.
Infinium Pharmachem Seeks Shareholder Nod to Migrate from NSE Emerge to Main Board
Infinium Pharmachem Limited has issued a Postal Ballot notice seeking shareholder approval to migrate its equity shares from the NSE Emerge SME platform to the Main Board of NSE. The company has been listed on NSE Emerge since April 17, 2023, and meets the eligibility threshold with a paid-up equity capital of ₹15.58 crore (1,55,83,120 shares of ₹10 each) and a market cap exceeding ₹300 crore (current market cap of ₹358 crore). The remote e-voting window runs from August 28, 2026 to September 26, 2026, with results expected on or before September 29, 2026. Per SEBI ICDR regulations, approval requires non-promoter votes in favour to be at least two times the votes against.
Confidence: HIGH
What changedInfinium Pharmachem has initiated the formal process to graduate from the SME platform (NSE Emerge) to the Main Board of NSE via postal ballot.
Why it mattersMigration to the Main Board removes SME lot-size constraints, allowing normal trading in single-share multiples, which typically improves liquidity, trading volume, and institutional participation.
Paid-up Share Capital: ₹15,58,31,200Total Equity Shares: 1,55,83,120E-Voting Start Date: 28th August, 2026E-Voting End Date: 26th September, 2026Results Date: on or before 29th September, 2026
📅 Short termShareholders holding shares as of August 21, 2026 can cast votes until September 26, 2026; trading liquidity will remain subject to SME rules until migration completes.
📈 Long termMainboard listing provides enhanced institutional visibility, improved price discovery, and greater access to broad capital markets as the business scales.
⚠ Risk flags
- Requires requisite approval where public non-promoter votes in favour must exceed twice the votes against
- Subject to final regulatory and technical approvals from the National Stock Exchange
Key Highlights
Proposed migration of 1,55,83,120 equity shares from NSE Emerge to the Main Board of NSE
Paid-up equity share capital stands at ₹15,58,31,200 comprising shares of ₹10 face value each
Remote e-voting period open from August 28, 2026 (9:00 AM) to September 26, 2026 (5:00 PM)
Voting results to be declared on or before September 29, 2026; cut-off date was August 21, 2026
Requires non-promoter approval ratio of at least 2:1 in favour as per SEBI ICDR Regulation 277
👀 What to Watch
Track the e-voting outcome on or before September 29, 2026, followed by the formal listing and in-principle approval timeline from the National Stock Exchange.
Infinium Pharmachem Approves Migration to NSE Main Board; Fixes AGM on Sept 17, 2026
Infinium Pharmachem's Board of Directors has approved the proposed migration of its equity shares from the NSE SME platform (NSE Emerge) to the Main Board of NSE, subject to shareholder approval via Postal Ballot. The company appointed Swastika Investmart Limited as the merchant banker for the migration process. Additionally, the Board scheduled the 22nd Annual General Meeting for September 17, 2026, setting September 10, 2026, as the record date. Auditor appointments for FY 2026-27 were also confirmed across secretarial, cost, and internal audit functions.
Confidence: HIGH
What changedThe Board approved the formal process and merchant banker appointment to migrate the company's listing from the SME segment to the NSE Main Board.
Why it mattersMigration to the Main Board removes the fixed lot size trading restrictions of SME exchanges, which typically enhances stock liquidity, broadens the retail and institutional shareholder base, and improves market visibility for a ₹346 Cr market-cap company.
AGM Date: September 17, 2026AGM Record Date: September 10, 2026Market Cap: Rs 346 CrTTM Revenue: Rs 346 Cr
📅 Short termPositive sentiment driven by the planned main-board graduation, though the formal transition requires completion of postal ballot voting and exchange approvals.
📈 Long termMain-board listing enables institutional investor participation and single-share trading liquidity, supporting future equity capital-raising and valuation discovery.
⚠ Risk flags
- Migration is subject to shareholder approval and regulatory clearance from the stock exchange
Key Highlights
Approved migration of equity shares from NSE SME Platform to NSE Main Board via Postal Ballot
Appointed Swastika Investmart Limited as Merchant Banker for the migration process
Scheduled 22nd Annual General Meeting for September 17, 2026
Fixed September 10, 2026 as the record date for the Annual General Meeting
Appointed RTBR & Associates (Secretarial), BRS & Associates (Cost), and Ronak R Jain & Associates (Internal) as auditors for FY 2026-27
👀 What to Watch
Track the outcome of the postal ballot voting for shareholder approval and subsequent in-principle listing approvals from NSE for the main-board migration.
